USD
+$0.00
(+0.00%
)At Close (As of Dec 12, 2025)
$717.98M
Market Cap
-
P/E Ratio
-2.16
EPS
$9.73
52 Week High
$4.55
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Operating Cashflow | -$104M |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $13M |
| Capital Expenditures | $5M |
| Change In Receivables | - |
| Change In Inventory | -$387K |
| Profit Loss | - |
| Cashflow From Investment | $23M |
| Cashflow From Financing | $55M |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | - |
| Dividend Payout Common Stock | - |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | - |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | -$148M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
MeiraGTx Holdings PLC is a clinical-stage gene therapy company based in New York, focused on pioneering treatments for severe genetic disorders using advanced gene-editing technologies. The company addresses significant unmet medical needs across therapeutic areas including ophthalmology, neurology, and rare diseases, positioning itself as a leader in genetic medicine. With a robust and diversified pipeline of innovative therapeutic solutions, MeiraGTx is dedicated to transforming patient care and hopes to set new standards in the treatment of complex genetic conditions.